FOLFIRINOX Adjuvant Therapy for Pancreatic Cancer

To the Editor: Conroy and colleagues (Dec. 20 issue) 1 present the results of the PRODIGE (Partenariat de Recherche en Oncologie Digestive) 24–CCTG PA (Canadian Cancer Trials Group Pancreatic Adenocarcinoma) 6 trial, which are changing the standard of care and prognosis for patients with resected pa...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 380; no. 12; pp. 1187 - 1189
Main Authors Vivaldi, Caterina, Fornaro, Lorenzo, Vasile, Enrico, Malka, David, Castan, Florence, Conroy, Thierry
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 21.03.2019
Subjects
Adenocarcinoma
Adjuvant therapy
Age
Cancer therapies
Clinical trials
Pancreatic cancer
France
Canada
Online AccessGet full text

Cover

More Information
Summary:To the Editor: Conroy and colleagues (Dec. 20 issue) 1 present the results of the PRODIGE (Partenariat de Recherche en Oncologie Digestive) 24–CCTG PA (Canadian Cancer Trials Group Pancreatic Adenocarcinoma) 6 trial, which are changing the standard of care and prognosis for patients with resected pancreatic adenocarcinoma. However, the low enrollment rate of approximately 1.5 patients per center per year, as compared with the number of patients with resected pancreatic cancer in France and Canada, 2,3 suggests a strict selection of patients. Therefore, to better understand how to translate these results into clinical practice and to compare them with those obtained with . . .
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ObjectType-Commentary-2
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMc1900712